By September 15, 2026: Billing team and clinical staff must access Anthem's Clinical Criteria page (https://providernews.anthem.com/california/articles/clinical-criteria-updates-31686) to download and review the complete clinical criteria documents for all 27 affected drugs (CC-0029, CC-0031, CC-0032, CC-0043, CC-0057, CC-0061, CC-0077, CC-0099, CC-0112, CC-0119, CC-0121, CC-0125, CC-0128, CC-0130, CC-0151, CC-0158, CC-0163, CC-0218, CC-0237, CC-0243, CC-0258, CC-0276, CC-0279, CC-0281, CC-0303, CC-0304, CC-0305, CC-0306). Identify which drugs your practice administers or prescribes. Before October 1, 2026: Update clinical documentation templates, prior authorization request forms, and billing system notes to reflect any new or revised medical necessity requirements for affected medications. Train providers and clinical staff on new documentation requirements for Dupixent, Krystexxa, Palynziq, oncology checkpoint inhibitors (Yervoy, Opdivo, Tecentriq, Imfinzi, Gazyva), CAR-T therapies (Yescarta), and new drugs (Hepcludex, Decnupaz, Lumvoa, Trutakna). Notify providers that authorization rules will be communicated separately and coordinate with Anthem to obtain those details. Failure to align with revised clinical criteria will result in claim denials for medical drug benefits covered under members' medical plans.